RPG Life Sciences Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Strong return on equity (ROE 19.3%)
- ✓Efficient capital deployment (ROCE 25.7%)
- ✓Attractively valued vs sector (P/E 43.1x vs industry 54.4x)
- ✓Virtually debt-free
Concerns
- ✗Trading near 52-week high (₹3,010)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
RPGLIFE · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 72.82% | 72.82% | 72.82% | 72.82% | 72.95% | 72.95% |
| FII | 0.56% | 0.90% | 1.15% | 1.35% | 1.30% | 1.46% |
| DII | 1.77% | 2.16% | 2.61% | 5.45% | 6.06% | 6.14% |
| Public | 24.85% | 24.12% | 23.44% | 20.40% | 19.70% | 19.46% |
Latest News
All news →RPG Life Sciences sees spurt in trading volume
*RPG Life Sciences sees spurt in trading volume* — RPG Life Sciences witnessed a significant spike in trading volume, prompting the NSE to seek clarification. The company has responded to the exchange's query to ensure transparency. No major corporate event was disclosed, suggesting the surge may be speculative. 📊 *STOCKS:* RPGLIFE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #VolumeSpurt
RPG Life Sciences launches Naprosyn ES in India
*RPG Life Sciences launches Naprosyn ES in India.* The company has introduced Naprosyn ES, an enhanced-release formulation of naproxen, targeting chronic pain conditions. This launch expands its presence in the anti-inflammatory segment. The product is expected to contribute to revenue growth in the coming quarters. 📊 *STOCKS:* RPGLIFE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ProductLaunch